Larimar Therapeutics (LRMR) Non Operating Income (2013 - 2025)

Larimar Therapeutics' Non Operating Income history runs 13 years deep, the most recent figure standing at $1.5 million for Q4 2025.

• Quarterly Non Operating Income fell 38.44% year-over-year to $1.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $6.8 million (down 33.66% YoY) and the FY2025 annual result came in at $6.8 million, down 33.66% from the prior year.
• Non Operating Income was $1.5 million for Q4 2025 at Larimar Therapeutics, down from $1.8 million in the prior quarter.
• Across five years, Non Operating Income topped out at $3.0 million in Q2 2024 and bottomed at -$75000.0 in Q3 2021.
• A 5-year average of $1.1 million and a median of $1.2 million in 2023 frame the typical range for Non Operating Income.
• Annual changes were most pronounced in 2022 — Non Operating Income sank 411.11% — and 2023, when it soared 6170.0%.
• Larimar Therapeutics' Non Operating Income stood at -$48000.0 in 2021, then surged by 2212.5% to $1.0 million in 2022, then advanced by 15.29% to $1.2 million in 2023, then surged by 111.21% to $2.5 million in 2024, then tumbled by 38.44% to $1.5 million in 2025.
• Business Quant data shows LRMR's Non Operating Income at $1.5 million in Q4 2025, $1.8 million in Q3 2025, and $1.6 million in Q2 2025.